Related Experiment Video
Updated: Jun 17, 2026
06:51
Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay
Published on: July 21, 2021
Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition
Huixia Zhang1, Isabelle Ragueneau-Majlessi, Rene H Levy
1Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195, USA.
Drug Metabolism Letters
|December 10, 2009
Summary
Clopidogrel, an antiplatelet medication, needs activation by CYP2C19. Proton pump inhibitors (PPIs) reduce its effectiveness, a finding potentially explained by clopidogrel also inhibiting CYP2C19.
Area of Science:
- Pharmacology
- Drug Metabolism
- Cardiovascular Medicine
Background:
- Clopidogrel is an antiplatelet agent requiring metabolic activation.
- Cytochrome P450 enzymes, particularly CYP2C19, are crucial for clopidogrel bioactivation.
- Co-administration with proton pump inhibitors (PPIs) is common to prevent gastrointestinal bleeding.
Purpose of the Study:
- To investigate the mechanism behind the reduced antiplatelet effect of clopidogrel when co-administered with PPIs.
- To explore the interaction between clopidogrel and CYP2C19 in the context of PPI use.
Main Methods:
- Review of existing literature on clopidogrel metabolism and PPI interactions.
- Analysis of pharmacokinetic data regarding CYP2C19 inhibition.
- Hypothesis formulation based on observed clinical data and enzyme kinetics.
Main Results:
- Observed decreased antiplatelet effect in patients taking clopidogrel with PPIs.
- Weak direct inhibition of CYP2C19 by PPIs does not fully explain the observed effect.
- Clopidogrel itself acts as an inhibitor of CYP2C19.
Conclusions:
- The interaction between clopidogrel and CYP2C19 may be bidirectional.
- Clopidogrel's auto-inhibition of CYP2C19 could contribute to reduced active metabolite formation when used with PPIs.
- Further research is warranted to elucidate the clinical significance of this interaction.
Related Concept Videos
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...